Accordingly, many current off-label therapies for NMO deplete B cells or modulate their activity.

Rituximab is an anti-CD20 antibody used to deplete B lymphocytes in lymphoma and autoimmune disease.

Current approaches use rituximab to deplete B cells or adoptive transfer of EBV cytotoxic T lymphocyte to reconstitute immunity.

One or 2 doses of RTX may be sufficient to deplete B cells and achieve better control of pediatric NS.

Therapeutic efficacy of depleting B cells or blocking T-cell costimulation in rheumatoid arthritis (RA) has confirmed the critical pathogenic role of adaptive immune responses.